RxDoctor Payments Data

Billy Pence, MD

Internal Medicine · Mars Hill, NCNPI 1588647390

Payments from drug & device makers

$600in general payments, 2019–2025

Across 27 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$124
  • Novo Nordisk$100
  • Lilly USA, LLC$80
  • AstraZeneca$64
  • Pfizer$47
  • Exact Sciences$45
  • plus $140 from 6 others

What the payments were for

  • Food & beverage$600100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$600 in reported general payments places this provider in the 65th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,525
Medicare patients
88
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban31$33,149
JardianceEmpagliflozin28$24,242
OzempicSemaglutide19$21,077
TrulicityDulaglutide11$14,458
EliquisApixaban13$7,285
Albuterol Sulfate HfaAlbuterol Sulfate35$1,009
Metformin Hcl ErMetformin Hcl15$984
CefuroximeCefuroxime Axetil89$911
Fluticasone Propionate76$873
Atorvastatin Calcium98$694
Nifedipine ErNifedipine58$685
Bupropion Hcl SrBupropion Hcl22$557
Gabapentin47$544
Omeprazole56$519
Metoprolol Succinate39$512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$124$24,24228 claims
Novo NordiskOzempic$100$21,07719 claims
Lilly USA, LLCTrulicity$80$14,45811 claims
PfizerEliquis$47$7,28513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Mars Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →